HHS IEA | COVID-19 Update for March 21, 2022

HHS Office of Intergovernmental and External Affairs COVID-19 Update for
March 21, 2022  
CASE UPDATE
New Cases (based on 7-day rolling average)

  • 79,571,321 U.S. cases
  • 17.3% decrease in new cases (7-day average), as of March 18, 2022

Testing

  • 837,949,940 tests completed (3/21)
  • 2.3% positive test rate as of the week of 3/11 – 3/17/22 (was 2.7 % last week)

Hospitalizations

  • 4,581,254 total COVID hospital admissions (3/18)
  • The 7-day average (3/12 – 3/18) number of new confirmed COVID-19 admissions decreased from 2,642 to 2,010 admissions per day

Deaths

  • 969,114 total U.S. deaths
  • The 7-day average (3/12 – 3/18) number of reported deaths decreased from 1,199 to 973 deaths per day

Vaccines

  • 558,678,770 vaccine doses administered (3/21/22)
  • 76.8% (255 million people) of the population has received 1 or more doses and 65.4% (217.1 million people) of the population have been fully vaccinated
  • 81.6% of people five years and older have received at least 1 dose and 69.5% have been fully vaccinated
VACCINE UPDATES
COVID-19 Vaccines Continue to Protect Against Hospitalization and Death Among Adults: CDC released a statement that COVID-19 vaccination continues to help protect adults against severe illness with COVID-19, including hospitalizations and death, according to two reports released in last week’s MMWR . During Omicron, COVID-19-associated hospitalization rates increased for all adults, regardless of vaccination status, but rates were 12 times higher among adults who were unvaccinated compared to adults who received a booster or additional doses. Hospitalization rates were also highest among non-Hispanic Black adults and nearly 4 times as high among Black adults than White adults during the peak of Omicron. CDC continues to recommend that everyone 5 years and older stay up to date on their COVID-19 vaccines, including a booster dose for those who are eligible. We also must work to ensure everyone has equitable access to vaccines and treatments by focusing efforts on reaching people who have been disproportionately affected, so that they can be protected from the effects of the virus, including severe illness, hospitalization, and death.

FDA to Hold Advisory Committee Meeting on COVID-19 Vaccines to Discuss Future Boosters: The U.S. Food and Drug Administration (FDA) announced a virtual meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Wednesday, April 6, to discuss considerations for future COVID-19 vaccine booster doses and the process for selecting specific strains of the SARS-CoV-2 virus for COVID-19 vaccines to address current and emerging variants. Along with the independent experts of the advisory committee, representatives from the U.S. Centers for Disease Control and Prevention and the National Institutes of Health will participate in the meeting.

One-Year Anniversary of Health Center COVID-19 Vaccine Program: Today, the U.S. Department of Health and Human Services (HHS) recognized the one-year anniversary of the Health Resources and Services Administration’s (HRSA)  Health Center COVID-19 Vaccine Program , which received funding from President Biden’s American Rescue Plan and has provided COVID-19 vaccines directly to thousands of HRSA-supported health center sites nationwide. To date, health centers have administered more than 20 million vaccines in underserved communities across the country through the HRSA program and partnerships with states.

TESTING AND TREATMENT
FDA Safety Communication on At-Home COVID-19 Tests: The FDA  issued a safety communication  to alert people of the potential for harm if FDA-authorized at-home COVID-19 tests are not used according to the manufacturer’s test instructions. The FDA is also reminding people to keep the tests out of reach from children and pets. The FDA has received reports of injuries caused by the incorrect use of at-home COVID-19 tests, such as people putting the test chemicals in their eyes, due to the small vials of test solution were mistaken for eye drops. The FDA is also aware of children putting small plastic vials in their mouth and swallowing test solution. This safety communication provides:

  • Recommendations for people using FDA-authorized at-home COVID-19 diagnostic tests
  • Background on the issue and the FDA’s actions
  • Instructions for reporting problems with at-home COVID-19 testing to the FDA

EUA for At-Home Test: The FDA issued an emergency use authorization (EUA) for PHASE Scientific International, Ltd.’s INDICAID COVID-19 Rapid Antigen At-Home Test, an OTC #COVID19 antigen diagnostic on March 16. The FDA is committed to increase the availability of appropriately accurate and reliable at-home COVID19 diagnostic tests, and to facilitate consumer access to these tests.

RESEARCH
COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance: CDC released an MMWR on COVID-19-associated hospitalizations among adults during SARS-CoV-2 Delta and Omicron variant predominance by race/ethnicity and vaccination status from fourteen states between July 2021 – January 2022. SARS-CoV-2 infections can result in COVID-19–associated hospitalizations, even among vaccinated persons. In January 2022, unvaccinated adults and those vaccinated with a primary series, but no booster or additional dose, were 12 and three times as likely to be hospitalized, respectively, as were adults who received booster or additional doses. Hospitalization rates among non-Hispanic Black adults increased more than rates in other racial/ethnic groups. All adults should stay up to date with COVID-19 vaccination to reduce their risk for COVID-19–associated hospitalization. Implementing strategies that result in the equitable receipt of COVID-19 vaccinations among persons with disproportionately higher hospitalizations rates, including non-Hispanic Black adults, is an urgent public health priority.

Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death: CDC released an MMWR on the effectiveness of mRNA vaccination in preventing COVID-19-associated invasive mechanical ventilation and death in the United States from March 2021 – January 2022. COVID-19 mRNA vaccines provide protection against COVID-19 hospitalization among adults. However, how well mRNA vaccines protect against the most severe outcomes of COVID-19–related illness, including use of invasive mechanical ventilation (IMV) or death, is uncertain. Receiving 2 or 3 doses of an mRNA COVID-19 vaccine was associated with a 90% reduction in risk for COVID-19–associated IMV or death. Protection of 3 mRNA vaccine doses during the period of Omicron predominance was 94%. COVID-19 mRNA vaccines are highly effective in preventing the most severe forms of COVID-19. CDC recommends that all persons eligible for vaccination get vaccinated and stay up to date with COVID-19 vaccination.

Marvin B. Figueroa, Director
U.S. Department of Health and Human Services
Intergovernmental and External Affairs
200 Independence Ave., S.W.
Washington, D.C. 20201

Connect With Us

 Visit the HHS YouTube account Visit the HHS IEA website Call us Email us

COVID-19 coronavirus, Department of Health and Human Services (HHS)